• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Clin Res Cardiol . Myocarditis mortality with and without COVID-19: insights from a national registry

tetano

Editor, Senior Moderator
Clin Res Cardiol


. 2022 Dec 24.
doi: 10.1007/s00392-022-02141-9. Online ahead of print.
Myocarditis mortality with and without COVID-19: insights from a national registry


Xavier Bemtgen[SUP] 1 [/SUP], Klaus Kaier[SUP] 2 [/SUP], Jonathan Rilinger[SUP] 3 [/SUP], Felix Rottmann[SUP] 4 [/SUP], Alexander Supady[SUP] 5 6 [/SUP], Constantin von Zur Mühlen[SUP] 3 [/SUP], Dirk Westermann[SUP] 3 [/SUP], Tobias Wengenmayer[SUP] 5 [/SUP], Dawid L Staudacher[SUP] 5 [/SUP]



Affiliations

Abstract

Background: Myocarditis in context of a SARS-CoV-2 infection is vividly discussed in the literature. Real-world data however are sparse, and relevance of the myocarditis diagnosis to outcome in coronavirus disease (COVID-19) is unclear.
Patients and methods: Retrospective analysis of 75,304 patients hospitalized in Germany with myocarditis between 2007 and 2020 is reported by DESTATIS. Patients hospitalized between 01/2016 and 12/2019 served as reference cohort for the COVID-19 patients hospitalized in 2020.
Results: A total of 75,304 patients were hospitalized between 2007 and 2020 (age 42.5 years, 30.1% female, hospital mortality 2.4%). In the reference cohort, 24,474 patients (age 42.8 years, 29.5% female, hospital mortality 2.2%) were registered. In 2020, annual myocarditis hospitalizations dropped by 19.6% compared to reference (4921 vs. 6119 annual hospitalization), of which 443/4921 (9.0%) were connected to COVID-19. In 2020, hospital mortality of myocarditis in non-COVID-19 patients increased significantly compared to reference (2.9% vs. 2.2%, p = 0.008, OR 1.31, 95% CI 1.08-1.60). In COVID-19 myocarditis, hospital mortality was even higher compared to reference (13.5% vs. 2.2%, p < 0.001, OR 6.93, 95% CI 5.18-9.18).
Conclusion: The burden of patients with myocarditis and COVID-19 in 2020 was low. Hospital mortality was more than sixfold higher in patients with myocarditis and COVID-19 compared to those with myocarditis but without COVID-19.

Keywords: COVID-19; Hospitalization; Myocarditis; National registry; SARS-CoV-2; Survival.
 
Back
Top Bottom